VivoSeq
Oncology

Tumor Microenvironment

0

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

Tumor Microenvironment is an early-stage landscape with 0 programs across 1 company. The most active players are Mural Oncology, Inc.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

33/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Mural Oncology, Inc

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Active, not recruiting2 · 29%
Withdrawn1 · 14%
Completed1 · 14%
Recruiting1 · 14%
Unknown status1 · 14%
Terminated1 · 14%

Clinical Trials

Trial Activity

7 trials

Lifei Xiaoji Wan Treatment's of Early-stage NSCLC and Its Impact on the Tumor Microenvironment
Recruiting·HHenan University of Traditional Chinese Medicine·N/A·NCT06387134·40 enrolled
Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)
Active, not recruiting·—·Phase 2·NCT03534635·30 enrolled
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Active, not recruiting·MMural Oncology, Inc·Phase 1/2·NCT04592653·78 enrolled
Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy
Completed·UUniversity of Erlangen-Nürnberg Medical School·Phase 2·NCT04225390·38 enrolled
Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration in NSCL Cancer Patients
Terminated·IInstitut Bergonié·Phase 2·NCT04880382·8 enrolled
Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients
Withdrawn·—·Phase 1·NCT06922825
Targeting the Tumor Microenvironment in R/M SCCHN
Unknown status·GGruppo Oncologico del Nord-Ovest·Phase 1/2·NCT03844763·71 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)